Zymeworks Inc

Zymeworks Inc. is a biopharmaceutical company. It engages in the discovery, development, and commercialization of multifunctional biotherapeutics, initially focused on the treatment of cancer. The company is headquartered in Middletown, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zymeworks reports turnaround year with strong financials and R&D progress

Zymeworks delivered a strong financial performance in 2022, driven by revenue growth and cost management efforts.
The company faces challenges in managing increased expenses and addressing analyst inquiries on data disclosure and product development.
Despite challenges, Zymeworks remains well-positioned with ample cash resources and a robust R&D pipeline for future growth.
Opportunities lie in expanding partnerships, leveraging positive trial data, and showcasing innovation at upcoming industry events.

Zymeworks Inc reports revenue growth and strategic R&D advancements

Zymeworks Inc's Q1 2023 performance reflects positive financial trends and advancements in their R&D programs and partnerships.
While challenges exist with the Jazz agreement and future clinical trials, the company is strategically positioned for growth.
Opportunities in global collaborations, capital allocation, and innovative therapies position Zymeworks for future success and market expansion.

Zymeworks reports improved financials, advances global clinical expertise

Zymeworks Inc's Q2 2023 performance reflects a mixed financial picture with revenue growth but increased expenses, while maintaining a healthy cash position.
The company's strengths lie in advancing its product pipeline, leveraging partnerships for efficient development, and establishing global clinical expertise.
Challenges include timeline uncertainties, competitive landscape considerations, and operational complexities in clinical trial development.
Opportunities abound in therapeutic advancements, strategic partnerships, and long-term financial sustainability through disciplined management.

Zymeworks Inc reports improved financials and optimistic drug outlook

Zymeworks Inc's Q3 2023 performance reflects improved financials driven by revenue growth from collaborations, cost management strategies, and operational streamlining.
The company's strengths lie in new IND candidates, positive outlook on key drug opportunities, and confidence in study designs and treatment efficacy.
Challenges include managing expense trajectories, balancing cost structures, and optimizing cash resources for sustained operations and growth.
Opportunities abound in continued collaboration benefits, pipeline expansion in targeted cancer therapies, and advancements in preclinical assets for future clinical studies.

Zymeworks accelerates pipeline development with positive clinical results and partnerships

Zymeworks demonstrated positive performance in clinical trials and financial management in Q4 2023.
Strengths lie in pipeline progress, resource independence, and potential milestone payments.
Challenges include financial losses, competition, and the need for strategic partnerships.
Opportunities exist in partnerships, milestone payments, and upcoming data readouts for market impact.

Zymeworks Inc reports Q1 loss, focuses on T cell enhancement

Zymeworks Inc is strategically positioned to advance its clinical development programs and strengthen its presence in key locations for upcoming trials. The company is committed to executing its plan efficiently, focusing on enhancing T cell responses and exploring opportunities for sustainable growth.

Zymeworks reports Q2 losses, advances oncology pipeline with FDA clearances

Zymeworks' Q2 2024 performance reflects a mix of financial challenges and strategic advancements in drug development and regulatory milestones.
The company's strengths lie in its pipeline progress, strategic decision-making, and focus on growth through key appointments and partnerships.
While facing challenges in financial metrics and product timelines, Zymeworks has opportunities to leverage its resources for future growth and innovation.

Zymeworks reports revenue decline but showcases strength in innovation and financial strategy

Zymeworks reported a decline in revenue and a net loss for Q3 2024, reflecting ongoing financial challenges.
Despite this, the company showcased strengths in preclinical data, share repurchase program, and commitment to innovation.
Navigating market conditions and managing expenses will be crucial, but Zymeworks has opportunities in new therapeutic areas and strategic initiatives.
Investors should monitor the company's progress, especially with the upcoming R&D Day and potential advancements in its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the departure of Neil Klompas, President and Chief Operating Officer.

Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer

Zymeworks Inc. (NASDAQ:ZYME ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kenneth Galbraith - Chairman, Chief Executive Officer Neil Klompas - President, Chief Operating Officer Paul Moore - Chief Scientific Officer Chris Astle - Senior Vice President, Chief Financial Officer Jack Spinks - Director of Investor Relations Conference Call Participants Stephen Willey - Stifel Charles Zhu - Guggenheim Partners Derek Archila - Wells Fargo Brian Cheng - JP Morgan Carly Kenselaar - Citi Phoebe Tan - Jefferies Operator Good day! And thank you for standing by.

Zymeworks Inc. (ZYME) Q1 2023 Earnings Call Transcript

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $1.19 per share a year ago.

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

VANCOUVER, British Columbia, May 08, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business highlights.

Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles ● ZW171 induced potent preferential killing of cancer cells and potential to mitigate risk of on-target off-tumor toxicity, peripheral T cell activation, and cytokine-release syndrome ● ZW251 exhibits desired target-mediated activity in vitro and robust anti-tumor activity in PDX models ● Management will host conference call today at 6:30 pm Eastern Daylight Time (EDT)

Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting

Ichor Hlds

Vishay Intertechnology

FGI Industries Ltd

Himax Tech

iTeos Therapeutics, Inc.

Momo

Heading into unchartered territory in the market, investors may take comfort in acquiring the most undervalued stocks. Primarily, the less-popular enterprises offer the advantage of being exactly that: not hogging the spotlight.

The 7 Most Undervalued Stocks You Need to Know About

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2023 at 4:30 p.m. Eastern Time (ET).

Zymeworks To Host First Quarter 2023 Results Conference Call

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Mr. Miller brings extensive commercial, corporate and business development, and senior leadership experience in oncology to the Zymeworks board of directors.

Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors

Zymeworks has an enterprise value approaching zero, as milestone drug development payments were paid to the company in 2022. A significant pipeline, with partners helping to finance drug trials, is worthy of consideration.

Zymeworks: Exciting Short Squeeze Candidate With Large Cash Holdings

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 – 19, 2023.

Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting

Zymeworks Inc. (NASDAQ: ZYME) stock is up almost 5% after beating analysts' expectations for revenue and earnings in its March 7, 2023 earnings report. The clinical-stage biopharmaceutical company is working on discovering, developing and commercializing multifunctional biotherapeutics.

Zymeworks Offers Hope for More than Just Long-Term Investors

Zymeworks Inc. (NASDAQ:ZYME ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Chris Astle - Senior Vice President & Chief Financial Officer Kenneth Galbraith - Chair & Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citi James Shin - Wells Fargo Stephen Willey - Stifel Brian Cheng - JPMorgan Charles Zhu - Guggenheim Andrew Berens - SVB Leerink David Martin - Bloom Burton Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Zymeworks Fourth Quarter and Full Year 2022 Results Conference Call.

Zymeworks Inc. (ZYME) Q4 2022 Earnings Call Transcript

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a summary of recent business highlights.

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results

Zanidatamab passed the key test in December that led to partner Jazz's opt-in. HERIZON-BTC-01 results exceeded expectations with a much longer duration of response.

Zymeworks: Completion Of Jazz Deal Provides New Life

Zymeworks Inc. (ZYME) closed the most recent trading day at $8.57, making no change from the previous trading session.

Zymeworks Inc. (ZYME) Flat As Market Sinks: What You Should Know

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7th, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 7th, 2023 at 4:30 p.m.

Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth

In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at the fourth-quarter conference call.

Can Zymeworks (ZYME) Beat Expectations This Earnings Season?

Jazz Pharmaceuticals

Shares of Zymeworks Inc. ZYME, rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ, -0.58% said their experimental cancer drug had an overall survival rate of 84% in patients being treated for a type of metastatic gastroesophageal adenocarcinoma after 18 months. The companies are testing zanidatamab in combination with chemotherapy as a first-line treatment in an open-label Phase 2 clinical trial.

Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 12.5 months Ongoing Phase 3 randomized clinical trial, HERIZON-GEA-01, has the potential to support regulatory submissions for zanidatamab in combination with chemotherapy as a therapeutic option for patients with advanced HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) DUBLIN and VANCOUVER, BC , Jan. 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced tolerability and efficacy results, including the first overall survival (OS) data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). The preliminary results showed that, at the time of analysis, the median OS had not yet been reached with a median duration of study follow-up of 26.5 months.

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Boeing

Caterpillar

Celsius Holdings

Chevron

Enphase Energy

GSX Techedu Inc.

JPMorgan Chase & Co

McDonald's

Merck

NIKE

Northern Oil and Gas

Visa

Two new Breakout Stocks for Week 3 with better than 10% short-term upside and two Dow 30 Picks. Average cumulative returns for 2023 are +21.37% YTD. This week 2 of 4 high-frequency breakout picks gained over 10% in less than a week with peak gains in VYGR +66.1%, RES +13.0%, LTRX +8.2%.

MDA Breakout Stocks Week 3 - January 2023: High-Frequency Gainers To Give You An Edge

The mean of analysts' price targets for Zymeworks Inc. (ZYME) points to a 65.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Zymeworks Inc. (ZYME)? Wall Street Analysts Think 65.75%

VANCOUVER, British Columbia--( BUSINESS WIRE )--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year.

News for Zymeworks Inc Stock (ZYME)